SCHEMBL2491467

SCHEMBL2491467

C[C](C)CCCC(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7779030 0.91 LMNA (0.48)
SCHEMBL7563578 0.88 LMNA (0.46)
SCHEMBL25219703 0.88 LMNA (0.46)
SCHEMBL29258030 0.88 LMNA (0.46)
SCHEMBL28179508 0.81 PTPN1 (0.45)
SCHEMBL79844 0.80
SCHEMBL17762348 0.79
SCHEMBL1190548 0.79
SCHEMBL28989063 0.78 PTPN1 (0.39)
SCHEMBL7863608 0.78 PTPN1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214644-A1 PERFUME PRECURSOR TAKASAGO INTERNATIONAL CORPORATION (JP) 2021-07-15 US claimed
US-10202322-B2 Resorcinol derivatives SUTTER BAY HOSPITALS (US) 2019-02-12 US claimed
EP-2673257-B1 PET/SPECT AGENTS FOR APPLICATIONS IN BIOMEDICAL IMAGING UNIV WASHINGTON (US) 2018-07-18 EP claimed
US-20180170846-A1 RESORCINOL DERIVATIVES SUTTER WEST BAY HOSPITALS 2018-06-21 US claimed
EP-2920225-B1 REACTION ACCELERATOR FOR A COPOLYMERISATION , ELECTRICAL-INSULATION TAPE, ELECTRICAL-INSULATION BODY, AND CONSOLIDATION BODY SIEMENS AG (DE) 2017-11-29 EP claimed
US-20150361103-A1 REACTION ACCELERATOR FOR A COPOLYMERISATION, ELECTRICAL-INSULATION TAPE, ELECTRICAL-INSULATION BODY, AND CONSOLIDATION BODY SIEMENS AKTIENGESELLSCHAFT (DE) 2015-12-17 US claimed
EP-2920225-A2 REACTION ACCELERATOR FOR A COPOLYMERISATION, ELECTRICAL-INSULATION TAPE, ELECTRICAL-INSULATION BODY, AND CONSOLIDATION BODY Siemens Aktiengesellschaft (DE) 2015-09-23 EP claimed
US-20140343260-A1 PET/SPECT AGENTS FOR APPLICATIONS IN BIOMEDICAL IMAGING WASHINGTON UNIVERSITY (US) 2014-11-20 US claimed
WO-2014118077-A2 REACTION ACCELERATOR FOR A COPOLYMERISATION, ELECTRICAL-INSULATION TAPE, ELECTRICAL-INSULATION BODY, AND CONSOLIDATION BODY SIEMENS AKTIENGESELLSCHAFT (DE) 2014-08-07 WO claimed
EP-2762512-A1 Reaction accelerator for a copolymerization, electrical insulation tape, electrical insulation body and consolidation body Siemens Aktiengesellschaft (DE) 2014-08-06 EP claimed
US-20040242870-A1 Cannbichromene derivative; aids therapy IMMUGEN PHARMACEUTICALS, INC. 2004-12-02 US claimed
US-20030171372-A1 Antiviral methods and compounds IMMUGEN PHARMACEUTICALS, INC. (US) 2003-09-11 US claimed
US-20030158191-A1 Cannabinol derivatives TRAVIS CRAIG R (US) 2003-08-21 US claimed
US-6541510-B2 Cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus, especially HIV. IMMUGEN PHARMACEUTICALS, INC. 2003-04-01 US claimed
JP-2002539246-A 2002-11-19 JP claimed
US-20020068738-A1 Antiviral methods and compounds IMMUGEN PHARMACEUTICALS, INC. 2002-06-06 US claimed
WO-2002026728-A2 ANTIVIRAL METHODS AND COMPOUNDS IMMUGEN PHARMACEUTICALS, INC. (US) 2002-04-04 WO claimed
EP-1189603-A2 TREATMENT OF IMMUNE DISEASES LIKE HIV DISEASE AND NEOPLASTIC DISORDERS Immugen Pharmaceuticals, Inc. (US) 2002-03-27 EP claimed
US-6274635-B1 ANTITUMOR AGENTS IMMUGEN PHARMACEUTICALS INC. 2001-08-14 US claimed
WO-2000056303-A2 TREATMENT OF IMMUNE DISEASES IMMUGEN PHARMACEUTICALS, INC. (US) 2000-09-28 WO claimed